Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins - Wikidata - wikimedia - TriplyDB

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

http://www.wikidata.org/entity/Q35924859

about

A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?Circulating biomarkers in advanced renal cell carcinoma: clinical applications Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Sunitinib in the treatment of metastatic renal cell carcinoma Sunitinib in solid tumors A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.A phase I study of sunitinib plus bevacizumab in advanced solid tumors.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.Renal cell carcinoma: where will the state-of-the-art lead us?Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy.Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528 Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib Biomarkers of response and resistance to antiangiogenic therapy.Biomarkers for anti-angiogenic therapy in cancer.Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

P2860

Q24606852-0FC60173-7F27-4640-BB6E-10B4CC25D7B7 Q26752752-8B102A6F-1C99-4E7B-A7F2-CEF97B21E450 Q26783895-46C9B4B0-6E64-48B0-A65A-C3528274E4BA Q26823035-07AD68B6-A63E-4240-9F2A-F539FF498E17 Q26825512-A173506A-360C-460F-AFFF-AA01021B6782 Q27023770-B433CCF8-8BC4-45B2-B519-ADC6317D3720 Q27320322-AF057FCA-8C05-4E55-8166-1125094E9A18 Q27853358-6DEF2D46-954A-4B7A-B997-F07A566A9A99 Q28072057-56A1B7F2-61B1-4BBA-9F61-48EFAA3EA636 Q28245467-B9D2E606-2EDC-4432-8AD8-F91BC899CF3B Q28304566-8239EB58-715A-4B9D-BB90-A9C72F268FF3 Q30472042-253AB45E-ECC1-4AE6-ABC1-83358F9C0393 Q33317794-6312BF1C-341F-4931-A28F-2857B719A6AA Q33386345-2489C954-C877-4058-8346-7D87431857A9 Q33410206-3F27A845-BBC5-4E65-97C2-FD33DCC63CAF Q33411581-392D2419-424E-4241-BE89-C905A88AB1ED Q33413742-57400AA4-DA70-4F61-8313-A84FA4E8BC83 Q33413979-28DA8EC1-0540-451D-9E04-6CA242E6AC5E Q33417933-DA32089D-FF01-4A69-BC8E-B5FAAE7AB41C Q33573760-EE01086B-EE5A-4BF4-AEF5-B46E53FA297E Q33581969-24F43C4A-2692-4FDC-AF53-7E2699BBAE20 Q33648995-3DF32998-1F75-424B-8F72-E080FB6EBF84 Q33692402-1C9AA9CA-F962-4721-9BA6-5A3CC2C9BC6A Q33710553-11A39F5E-61B0-4ECA-AF5A-D6BB134FC60D Q34000345-0817A909-6983-441D-ACFA-86EFF6BFBD1E Q34003335-CBACDE47-8CC5-4D48-86C2-3E27686F81DD Q34160164-1ECF8935-8399-4ED7-8909-729067BAFA17 Q34265694-1C5486CE-41DE-4092-B09A-87173DDF9655 Q34266010-D091134A-30F0-40FA-8371-9175A729D5CD Q34322552-751D9960-CB34-405C-9390-5AD9F1AC8728 Q34337865-B4A652FE-B6CD-422C-834D-05CAF3D2CD87 Q34356881-7558B780-FDAB-4891-877D-F9CEBBE65CF7 Q34365135-410BE10E-5DD9-476A-AC5C-8F84A94A037C Q34499668-A64927C8-6F5B-4CE6-80DE-9E43C4A0C0AC Q34504397-566B88FE-1E3F-4D0D-B9CC-B664F3B9A02C Q34578277-05C52646-2216-46F6-97B4-2E644A78B667 Q34625305-3505F38B-5D20-44C5-B62B-909FE0A777D7 Q34673567-5BB76A52-C2AE-4C59-90C7-E390BF453A4C Q34695003-854C0FE6-8AD7-44C2-9B04-586CE7EE370A Q34745991-0DB030A5-0023-4598-8323-44D57041DDEC

P2860

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

http://www.wikidata.org/entity/Q35924859

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Circulating protein biomarkers ...... VEGF and VEGF-related proteins

@ast

Circulating protein biomarkers ...... VEGF and VEGF-related proteins

@en

type

label

Circulating protein biomarkers ...... VEGF and VEGF-related proteins

@ast

Circulating protein biomarkers ...... VEGF and VEGF-related proteins

@en

prefLabel

Circulating protein biomarkers ...... VEGF and VEGF-related proteins

@ast

Circulating protein biomarkers ...... VEGF and VEGF-related proteins

@en

P1433

Q35924859-6E6DDCF0-1592-44B7-9DC8-7364A0A79C21

P1476

Q35924859-48579079-6AC1-4F85-83DA-A7CE91A149D1

P2093

Q35924859-239D92BD-2D1F-4E7C-94B3-4840FD7D0956

Q35924859-3DF26FBC-B3F6-42F9-B850-30737C903C90

Q35924859-54969A88-92D8-4046-A401-8AAB61267B0A

Q35924859-634DF0A3-107C-42CE-B410-619A42DD7916

Q35924859-88131F7A-FECD-4E6B-B745-88B6FF071412

Q35924859-AC0EFA30-6866-43E3-825D-B0F5CBA5712A

P2860

Q35924859-0D6A6D2D-47A5-4578-AE79-963D2F373630

Q35924859-149DAB2C-B697-4B8D-980D-2E84D2166343

Q35924859-183920AB-BEBC-41CE-A669-BC0ECA0089DE

Q35924859-1CFCF7DB-C04C-4751-BB22-D90AF40A06C9

Q35924859-1E5E3BF7-01F0-49D9-A8E0-6FD577D90CA6

Q35924859-1F4744BA-C95D-450B-B5E8-D36DCF66626B

Q35924859-24524438-C382-4277-A46F-10F51AE7A5F2

Q35924859-26FA5B3A-CD80-4A9A-AC65-B3E88799A629

Q35924859-35BB844B-9FB4-46BF-BDA8-52AB6066C1CD

Q35924859-386913BC-FCF6-4D19-BB59-E0C5570C0641

P2888

Q35924859-6E35538D-AF31-4375-BE42-952F57D2A78E

P304

Q35924859-38739BB3-96DC-4463-9FB5-8FE72518D920

P31

Q35924859-6090CF34-7479-414F-AA09-F9F3F09CFAF4

P356

Q35924859-52BD13FE-CD8D-41C9-87F1-94336DCC484E

P478

Q35924859-CAEE4616-DC39-4580-8104-634AC1B92FC8

P50

Q35924859-2F17A10A-05B5-4469-B826-4C495412EB02

Q35924859-3B051F60-63B3-44A5-A9DA-956F2C8B87C4

P577

Q35924859-680D1C20-CF86-4543-AE4B-9CB788A3C9B1

P5875

Q35924859-078F37D7-BB06-45C0-A08D-72A212B8C1FD

P6179

Q35924859-2B659364-D40E-4D8F-8EEE-4BCA1C2A3B7A

P698

Q35924859-08AC153B-E2FA-4762-9259-1359EC1E6F74

P921

Q35924859-E01FA630-0B60-4A8F-8822-674F4FC63C1D

P932

Q35924859-46E6F8C2-30CF-4B62-B647-43199DD5034B

P356

P1433

Journal of Translational Medicine

P1476

Circulating protein biomarkers ...... VEGF and VEGF-related proteins

@en

P2093

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Carlo L Bello

http://www.w3.org/2001/XMLSchema#string

Charles M Baum

http://www.w3.org/2001/XMLSchema#string

Dominic Spinella

http://www.w3.org/2001/XMLSchema#string

John Smeraglia

http://www.w3.org/2001/XMLSchema#string

Samuel E Deprimo

http://www.w3.org/2001/XMLSchema#string

P2860

The role of pericytes in blood-vessel formation and maintenance

Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

The biology of VEGF and its receptors

Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis

Cancer statistics, 2005

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

RETRACTED: Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum

P2888

P304

32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-5-32

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

M. Dror Michaelson

P577

2007-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6231479

http://www.w3.org/2001/XMLSchema#string

P6179

1001875982

http://www.w3.org/2001/XMLSchema#string

P698

17605814

http://www.w3.org/2001/XMLSchema#string

P921

P932

1939830

http://www.w3.org/2001/XMLSchema#string